Indacaterol Acetate/Mometasone Furoate

醋酸茚达特罗/莫米松糠酸酯

Report date: 2026/05/26 20:00:28

Base Information

Drug NameIndacaterol Acetate/Mometasone Furoate
Drug Alias NameMometasone/indacaterol莫米松糠酸酯/醋酸茚达特罗乙酸茚达特罗莫米松糠酸酯Mometasone Furoate and Indacaterol Acetate莫米松糠酸酯乙酸茚达特罗 +[15] 
ClassificationSmall molecules > Steroids
Mechanisms of ActionGlucocorticoid receptor agonistsBeta-2 adrenergic receptor agonists
TargetsBeta-2 adrenergic receptorGlucocorticoid receptor
Therapy Area/IndicationsPulmonary Disease, Chronic ObstructiveAsthma
Global Approved IndicationsAsthma
Approved Indications in ChinaAsthma
Original Approved Country/TerritoryEU
Original Approved Date2020/05/30
Country/TerritoryCzechiaBelgiumBulgaria +[53] 
CombinationsYes Indacaterol MaleateMometasone furoate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma AgGlenmark Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesValeo Pharma IncNovartis Pharma AgNovartis Europharm Ltd +[5] 
Inactive CompaniesBeijing Kangchuanglian Biopharmaceutical Technology Research Co LtdNovartis Pharma Stein AgCspc Heibei Zhongrun Pharmaceutiacl Co Ltd
Active IndicationsAsthma
Inactive IndicationsPulmonary Disease, Chronic Obstructive

Other Information

ATC CodeR03AK
Related LinksN/A